Therefore, the two-year prospective cohort study in northern India evaluated 71 PLHIV, comparing those with advanced disease (WHO stage 3/4 or CD4 <200/µL) against those with stable disease. After excluding patients on mechanical ventilation, inotropes, or corticosteroids, researchers used the Acton Prolongatum stimulation test—measuring serum cortisol at 0, 60, and 120 minutes—to assess the prevalence of adrenal insufficiency and track six-month mortality outcomes.
Key Clinical Findings of the Study Includes:
High AI Prevalence: Assessments revealed an unexpectedly high occurrence of AI, affecting 30.56% of advanced disease participants and 71.43% of stable participants when utilizing a stimulated cortisol threshold of less than 19.5 µg/dL.
Hyponatremia as a Predictor: Analysis identified hyponatremia as a highly significant predictive variable for AI development, explicitly noted in 91% of advanced HIV patients with AI compared to 48% of those without it.
Steroid Metabolism Shifts: Evaluations demonstrated that patients with advanced HIV exhibited significantly elevated median basal cortisol levels (14.3 vs. 10.3 µg/dL) and a markedly higher cortisol/DHEA-S ratio (63.9% vs. 5.7%) compared to the stable group.
Mortality Indicators: Data confirmed that higher basal cortisol levels, diminished CD4 counts, adverse cortisol/DHEA-S ratios, and concurrent opportunistic infections were strongly associated with increased mortality.
The results suggest that adrenal insufficiency is a remarkably prevalent yet underdiagnosed complication among PLHIV, with 75% of advanced patients notably demonstrating low DHEA-S levels alongside altered cortisol responses, emphasizing the necessity of accurate endocrine evaluations.
Thus, the study concludes clinicians should gently consider implementing routine adrenal screening protocols when HIV-positive patients initially present to antiretroviral therapy centers, particularly by keeping a watchful eye on hyponatremia as a guiding indicator for further testing.
The relatively small sample size, the short six-month follow-up window, and the lack of diagnostic confirmation using the gold-standard synacthen test serve as modest limitations to this cohort study. Consequently, pursuing further research with larger sample sizes and exploring low-dose stimulation alternatives could delicately refine our understanding of adrenal dysfunction in this vulnerable patient population.
Reference
Choppala P, Vutukuri SS, Kattamuri L, Sethi P, Nischal N, Khadgawat R, et al. Prevalence and clinical associations of adrenal dysfunction in people living with human immunodeficiency virus: A prospective cohort study. Indian J Endocr Metab 2025;29:652-8.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.